Literature DB >> 23476737

Initial management strategies for follicular lymphoma.

Qiushi Chen1, Turgay Ayer, Loretta J Nastoupil, Miray Seward, Hongzheng Zhang, Rajni Sinha, Christopher R Flowers.   

Abstract

Follicular lymphoma (FL) can vary markedly in its initial presentation, and no single standard approach for its initial management has been adopted. Available options for the initial management of FL include watchful waiting, radiation, single-agent rituximab and combination of rituximab and chemotherapy with strategies segregated for patients who have low and high tumor burden disease based on established criteria. However, marked debate occurs regarding the role of watchful waiting in the modern era for low tumor burden, asymptomatic patients, the optimal timing of rituximab, the selection of chemotherapy regimen to partner with rituximab in high tumor burden patients, and strategies for the management of relapsed disease. We provide an evidence-based discussion on these and other issues regarding the management of FL, and propose a mathematical modeling approach for addressing some of these questions.

Entities:  

Year:  2012        PMID: 23476737      PMCID: PMC3587762          DOI: 10.2217/ijh.12.7

Source DB:  PubMed          Journal:  Int J Hematol Oncol        ISSN: 2045-1393


  45 in total

1.  Phase II/III study of R-CHOP-21 versus R-CHOP-14 for untreated indolent B-cell non-Hodgkin's lymphoma: JCOG 0203 trial.

Authors:  Takashi Watanabe; Kensei Tobinai; Taro Shibata; Kunihiro Tsukasaki; Yasuo Morishima; Nobuo Maseki; Tomohiro Kinoshita; Takayo Suzuki; Motoko Yamaguchi; Kiyoshi Ando; Michinori Ogura; Masafumi Taniwaki; Naokuni Uike; Kengo Takeuchi; Shigeru Nawano; Takashi Terauchi; Tomomitsu Hotta
Journal:  J Clin Oncol       Date:  2011-09-19       Impact factor: 44.544

2.  Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Authors:  M Dreyling
Journal:  Ann Oncol       Date:  2010-05       Impact factor: 32.976

3.  Using engineering control principles to inform the design of adaptive interventions: a conceptual introduction.

Authors:  Daniel E Rivera; Michael D Pew; Linda M Collins
Journal:  Drug Alcohol Depend       Date:  2006-12-13       Impact factor: 4.492

4.  Recommendations for the use of yttrium-90 ibritumomab tiuxetan in malignant lymphoma.

Authors:  Oliver Weigert; Tim Illidge; Wolfgang Hiddemann; Martin Dreyling
Journal:  Cancer       Date:  2006-08-15       Impact factor: 6.860

5.  Ofatumumab demonstrates activity against rituximab-sensitive and -resistant cell lines, lymphoma xenografts and primary tumour cells from patients with B-cell lymphoma.

Authors:  Matthew J Barth; Francisco J Hernandez-Ilizaliturri; Cory Mavis; Ping-Chiao Tsai; John F Gibbs; George Deeb; Myron S Czuczman
Journal:  Br J Haematol       Date:  2011-12-09       Impact factor: 6.998

6.  CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma.

Authors:  Robert Marcus; Kevin Imrie; Andrew Belch; David Cunningham; Eduardo Flores; John Catalano; Philippe Solal-Celigny; Fritz Offner; Jan Walewski; Joäo Raposo; Andrew Jack; Paul Smith
Journal:  Blood       Date:  2004-10-19       Impact factor: 22.113

7.  Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma.

Authors:  Franck Morschhauser; John Radford; Achiel Van Hoof; Umberto Vitolo; Pierre Soubeyran; Herve Tilly; Peter C Huijgens; Arne Kolstad; Francesco d'Amore; Marcos Gonzalez Diaz; Mario Petrini; Catherine Sebban; Pier Luigi Zinzani; Marinus H J van Oers; Wim van Putten; Angelika Bischof-Delaloye; Ama Rohatiner; Gilles Salles; Jens Kuhlmann; Anton Hagenbeek
Journal:  J Clin Oncol       Date:  2008-10-14       Impact factor: 44.544

8.  Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule.

Authors:  Michele Ghielmini; Shu-Fang Hsu Schmitz; Sergio B Cogliatti; Gabriella Pichert; Jörg Hummerjohann; Ursula Waltzer; Martin F Fey; Daniel C Betticher; Giovanni Martinelli; Fedro Peccatori; Urs Hess; Emanuele Zucca; Roger Stupp; Tibor Kovacsovics; Claudine Helg; Andreas Lohri; Mario Bargetzi; Daniel Vorobiof; Thomas Cerny
Journal:  Blood       Date:  2004-02-19       Impact factor: 22.113

9.  Effectiveness of first-line management strategies for stage I follicular lymphoma: analysis of the National LymphoCare Study.

Authors:  Jonathan W Friedberg; Michelle Byrtek; Brian K Link; Christopher Flowers; Michael Taylor; John Hainsworth; James R Cerhan; Andrew D Zelenetz; Jamie Hirata; Thomas P Miller
Journal:  J Clin Oncol       Date:  2012-08-20       Impact factor: 44.544

10.  Multiparameter calibration of a natural history model of cervical cancer.

Authors:  Jane J Kim; Karen M Kuntz; Natasha K Stout; Salaheddin Mahmud; Luisa L Villa; Eduardo L Franco; Sue J Goldie
Journal:  Am J Epidemiol       Date:  2007-05-25       Impact factor: 4.897

View more
  4 in total

1.  Lichenoid mucosal reaction to rituximab.

Authors:  Michal Kuten-Shorrer; Ephraim P Hochberg; Sook-Bin Woo
Journal:  Oncologist       Date:  2014-08-28

Review 2.  Microsimulation Modeling in Oncology.

Authors:  Çağlar Çağlayan; Hiromi Terawaki; Qiushi Chen; Ashish Rai; Turgay Ayer; Christopher R Flowers
Journal:  JCO Clin Cancer Inform       Date:  2018-12

3.  Efficacy and Safety of ABP 798: Results from the JASMINE Trial in Patients with Follicular Lymphoma in Comparison with Rituximab Reference Product.

Authors:  Dietger Niederwieser; Caroline Hamm; Patrick Cobb; Mindy Mo; Cecily Forsyth; Alessandra Tucci; Vladimir Hanes; Vincent Delwail; Roman Hajek; David Chien
Journal:  Target Oncol       Date:  2020-10       Impact factor: 4.493

4.  Oral Lichenoid Reaction: An Uncommon Side Effect of Rituximab.

Authors:  Amerigo Giudice; Francesco Liborio; Fiorella Averta; Selene Barone; Leonzio Fortunato
Journal:  Case Rep Dent       Date:  2019-11-06
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.